SpyGlass Pharma Reports Q4 and FY2025 Financial Results

What Happened
SpyGlass Pharma, Inc. (SGP) filed a Form 8-K on March 26, 2026 (Item 2.02) to announce its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the 8-K. The report was signed by Chief Financial Officer Jean-Frédéric Viret, Ph.D.

Key Details

• The 8-K was filed and the press release was furnished on March 26, 2026.
• The results cover the fourth quarter and the full fiscal year ended December 31, 2025.
• The press release is included as Exhibit 99.1 to the current report.
• The filing includes a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.

Why It Matters
This filing notifies investors that SpyGlass has publicly reported its latest quarterly and annual financial performance. Retail investors should read the furnished press release (Exhibit 99.1) for specific metrics—revenue, net income or loss, EPS, and any commentary on operations or guidance—and watch for follow-up filings (e.g., Form 10-K or earnings presentation) for detailed audited financial statements and management discussion.